Press Release Archive
Press Releases
May 2022
05.04.2022 Medicines Research Pfizer Presents Positive Real-World Evidence for First-Line IBRANCE® (palbociclib) Combination Therapy in HR+, HER2- Metastatic Breast Cancer at ESMO Breast Cancer 2022
April 2022
04.28.2022 Research Pfizer to Open First U.S. Sites in Phase 3 Trial of Investigational Gene Therapy for Ambulatory Patients with Duchenne Muscular Dystrophy 04.08.2022 Medicines Research Three Year Follow-Up Data from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) Confirm Prolonged Progression-Free Survival in First-Line ALK-Positive Advanced Lung Cancer
February 2022
02.14.2022 Research Biohaven and Pfizer Announce Positive Top-Line Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea 02.04.2022 Research Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate
January 2022
01.18.2022 Covid-19 Research Pfizer Shares In Vitro Efficacy of Novel COVID-19 Oral Treatment Against Omicron Variant 01.12.2022 Covid-19 Research Vaccines Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released 01.10.2022 Research Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics 01.10.2022 Partnerships Research Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
December 2021
12.20.2021 Medicines Research Pfizer’s VYNDAQEL®/VYNDAMAX® Reduced the Risk of All-Cause Mortality by 41% Among Patients with Transthyretin Amyloid Cardiomyopathy, Five-Year Follow-Up Data Demonstrate 12.17.2021 Covid-19 Research Vaccines Pfizer and BioNTech Provide Update on Ongoing Studies of COVID-19 Vaccine 12.15.2021 Research Pfizer Invests $68.5 Million in New State-of-the-Art Facility in Durham, North Carolina to Further Advance Gene Therapy Capabilities
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.